Squarepoint Ops LLC Has $582,000 Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Squarepoint Ops LLC boosted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 125.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,901 shares of the company's stock after buying an additional 9,411 shares during the quarter. Squarepoint Ops LLC's holdings in Harmony Biosciences were worth $582,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. KBC Group NV lifted its position in shares of Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after purchasing an additional 819 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after acquiring an additional 519 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in Harmony Biosciences by 34.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company's stock worth $137,000 after purchasing an additional 1,029 shares in the last quarter. CIBC Private Wealth Group LLC grew its position in shares of Harmony Biosciences by 66.4% during the fourth quarter. CIBC Private Wealth Group LLC now owns 4,214 shares of the company's stock worth $146,000 after buying an additional 1,681 shares in the last quarter. Finally, Sandia Investment Management LP purchased a new stake in shares of Harmony Biosciences during the fourth quarter worth approximately $172,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Harmony Biosciences Stock Performance

HRMY stock traded up $0.54 during midday trading on Friday, hitting $35.57. 209,333 shares of the company traded hands, compared to its average volume of 612,826. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 16.86, a price-to-earnings-growth ratio of 0.47 and a beta of 0.87. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The business has a 50 day simple moving average of $31.70 and a 200-day simple moving average of $34.03.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $184.73 million for the quarter, compared to analyst estimates of $184.26 million. During the same period last year, the business posted $0.67 EPS. Harmony Biosciences's revenue was up 19.5% compared to the same quarter last year. As a group, equities research analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analyst Weigh In

HRMY has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 target price on the stock. Oppenheimer began coverage on Harmony Biosciences in a research report on Monday. They issued an "outperform" rating and a $61.00 price objective for the company. Needham & Company LLC restated a "buy" rating and set a $49.00 price objective on shares of Harmony Biosciences in a report on Tuesday, May 6th. Mizuho increased their price target on Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a report on Thursday, May 15th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $53.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.